The purpose of this column is to highlight and summarize recent key patents in the pharmaceutical arena issued by the US Patent Office in June-July, 2026.
The goal is not to eliminate plates. It is to reduce the number of reasons to open or intervene in the isolator. By supplementing traditional environmental monitoring with real-time BFPC, manufacturers can preserve the value of growth-based methods while reducing avoidable interventions—and, consequently, the number of investigations triggered by the monitoring process itself.
Considering the advances in aseptic processing and their effectiveness in eliminating the primary sources of contamination (i.e., human activity), it is not our intent to entirely disparage the value of monitoring. Environmental monitoring has some value in trend analysis within an overall contamination control strategy. However, it is not a control mechanism.
As the sterile fill finish market continues to grow, the role of specialized drug delivery CDMO partnerships must shift from baseline execution to long-term future-proofing. Experienced partners add the highest value by anticipating how shifting global regulatory expectations and future market demands will impact a molecule years after its initial validation.
As technology in endotoxins and pyrogens testing changes, and as the basic research advances our understanding of pyrogenicity, fifty-year-old assumptions and decisions should be revisited, if not challenged. Given that it is neither typical nor representative of potential contaminants, is the current calibrant still an appropriate analyte for endotoxins and pyrogens testing?
The synthesis and evaluation of novel polymers have provided highly effective and safer alternatives to PEG in mRNA-LNP formulations, directly confronting the fundamental challenge of the PEG dilemma. This dilemma is the primary bottleneck for advanced nucleic acid therapeutics.